# Phase 1 lung cancer trials recruiting: 85 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 85 trials in phase 1 for lung cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 lung cancer trials: 85 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lung-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 85
- Recruiting or not yet: 85
- Read on: November 19, 2026

## Trials

The 25 newest of 85, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947043 | Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection | Tongji Hospital | Phase 1 | Recruiting | Recurrent or Metastatic Lung Cancer or Cervical Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947043) |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 2, 2026 | NCT07910942 | A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer | Kanvas Biosciences | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910942) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 5, 2026 | NCT07857616 | SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non... | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857616) |
| September 11, 2026 | NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815951) |
| August 24, 2026 | NCT07782359 | Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib | University of Chicago | Phase 1 | Recruiting | Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782359) |
| August 19, 2026 | NCT07772895 | Pemefolacianine for IMI of Lung Cancer | Sponsor not shown (see the record) | Phase 1 | Recruiting | Lung Cancer (Locally Advanced or Metastatic) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07772895) |
| June 30, 2026 | NCT07675876 | Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer | Carcinex Inc | Phase 1 | Not yet recruiting | Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675876) |
| June 12, 2026 | NCT07645222 | PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC | Hansoh BioMedical R&D Company | Phase 1 | Recruiting | Lung Cancer | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645222) |
| June 2, 2026 | NCT07619599 | A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer... | City of Hope Medical Center | Phase 1 | Recruiting | Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619599) |
| May 13, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A\*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | Corregene Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583316) |
| April 20, 2026 | NCT07538973 | A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Lung Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538973) |
| April 9, 2026 | NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519655) |
| March 27, 2026 | NCT07495098 | Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer | University of Vermont | Phase 1 | Not yet recruiting | Lung Cancer Metastatic, Lung Cancer (NSCLC) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495098) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| March 3, 2026 | NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Whitehawk Therapeutics, Inc. | Phase 1 | Recruiting | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR... | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444814) |
| February 27, 2026 | NCT07436858 | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing... | The Netherlands Cancer Institute | Phase 1 | Recruiting | Lung Cancer (NSCLC), HER2 Expression, HER2 Gene Mutation | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436858) |
| February 17, 2026 | NCT07414953 | A Phase Ib Study of HS-10504 Combined Therapy in NSCLC | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Lung Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414953) |
| February 5, 2026 | NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Recruiting | Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390838) |
| January 16, 2026 | NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal... | 574 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349537) |
| January 2, 2026 | NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | Nuvectis Pharma, Inc. | Phase 1 | Recruiting | EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07315113) |
| December 10, 2025 | NCT07274852 | A Study of Lutetium \[177Lu\]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07274852) |
| December 3, 2025 | NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | The First Affiliated Hospital of Xinxiang Medical College | Phase 1 | Recruiting | Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer, Cancer Treatment, Immunotherapy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260591) |
| November 24, 2025 | NCT07244835 | A Study of DEG6498 in Participants With Solid Tumors | Degron Therapeutics Co. | Phase 1 | Recruiting | Malignant Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244835) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Second Affiliated Hospital of Guangzhou Medical University | 5 |
| SystImmune Inc. | 3 |
| M.D. Anderson Cancer Center | 2 |
| City of Hope Medical Center | 2 |
| Ohio State University Comprehensive Cancer Center | 2 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 2 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 2 |
| Emory University | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| Shanghai Chest Hospital | 1 |
| Degron Therapeutics Co. | 1 |
| University of Pennsylvania | 1 |
| Kestrel Therapeutics, Inc. | 1 |
| RasCal Therapeutics, Inc. | 1 |
| University of California, Davis | 1 |
| Massachusetts General Hospital | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| GONGCHU Biotechnology Co., Ltd | 1 |
| Tongji Hospital | 1 |
| Nammi Therapeutics Inc | 1 |
| Guangzhou JOYO Pharma Co., Ltd | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| [Nanjing Sanhome Pharmaceutical, Co., Ltd.](https://specstream.ai/data/clinical-trials/company/nanjing-sanhome-pharmaceutical-co-ltd) | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 49 |
| China | 26 |
| Canada | 7 |
| Spain | 7 |
| France | 5 |
| Australia | 4 |
| South Korea | 4 |
| Netherlands | 3 |
| Belgium | 2 |
| Japan | 2 |
| Denmark | 1 |
| United Kingdom | 1 |
| Ireland | 1 |
| Portugal | 1 |
| Taiwan | 1 |
| Brazil | 1 |
| Mexico | 1 |
| Italy | 1 |
| Puerto Rico | 1 |
| Lebanon | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [EMS training centers in the United States](https://specstream.ai/data/businesses/ems-training-centers/united-states)
- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Business consulting firms in the United States](https://specstream.ai/data/businesses/business-consulting-firms/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Women's health clinics in the United States](https://specstream.ai/data/businesses/womens-health-clinics/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
